Targeting CD14 on blood derived cells improves intracortical microelectrode performance
| Autor: | Jeffrey B. Capadona, Ashley Rein, Madhumitha Ravikumar, John K. Hermann, Emily Molinich, Xujia Li, Stephen M. Selkirk, Robert H. Miller, Hillary W. Bedell, Steven Sidik, Shushen Lin, Dawn M. Taylor, Patrick Smith |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
Silicon CD14 Lipopolysaccharide Receptors Biophysics Bioengineering 02 engineering and technology Article Biomaterials 03 medical and health sciences 0302 clinical medicine Electric Impedance medicine Animals Humans Neuroinflammation Brain–computer interface Neurons Blood Cells Innate immune system Microglia Chimera business.industry Macrophages Brain 021001 nanoscience & nanotechnology Electrodes Implanted Mice Inbred C57BL Microelectrode Electrophysiology medicine.anatomical_structure Gliosis Mechanics of Materials Brain-Computer Interfaces Ceramics and Composites Female medicine.symptom 0210 nano-technology business Microelectrodes Neuroscience 030217 neurology & neurosurgery |
| Zdroj: | Biomaterials. 163:163-173 |
| ISSN: | 0142-9612 |
| DOI: | 10.1016/j.biomaterials.2018.02.014 |
| Popis: | Intracortical microelectrodes afford researchers an effective tool to precisely monitor neural spiking activity. Additionally, intracortical microelectrodes have the ability to return function to individuals with paralysis as part of a brain computer interface. Unfortunately, the neural signals recorded by these electrodes degrade over time. Many strategies which target the biological and/or materials mediating failure modes of this decline of function are currently under investigation. The goal of this study is to identify a precise cellular target for future intervention to sustain chronic intracortical microelectrode performance. Previous work from our lab has indicated that the Cluster of Differentiation 14/Toll-like receptor pathway (CD14/TLR) is a viable target to improve chronic laminar, silicon intracortical microelectrode recordings. Here, we use a mouse bone marrow chimera model to selectively knockout CD14, an innate immune receptor, from either brain resident microglia or blood-derived macrophages, in order to understand the most effective targets for future therapeutic options. Using single-unit recordings we demonstrate that inhibiting CD14 from the blood-derived macrophages improves recording quality over the 16 week long study. We conclude that targeting CD14 in blood-derived cells should be part of the strategy to improve the performance of intracortical microelectrodes, and that the daunting task of delivering therapeutics across the blood-brain barrier may not be needed to increase intracortical microelectrode performance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect